Abstract #3491

CBV-informed MR Fingerprinting for Improved Classification of Intratumoral Heterogeneity in Post-Treatment Glioblastomas

Shengwen Deng¹, Kaustav Bera¹, Nisha R. Korakavi¹, Walter Zhao^2,3, Sree Gongala^1,2, Parisa Arjmand^1,2, Eunate Alzaga², Tiffany R. Hodges^3,4,5, Prashant Vempati^3,5,6, Michael D. Staudt^3,4,5, Herbert Newton^3,4,7, David W. Jordan^1,3, Mark Griswold^2,3,8, Dan Ma^2,3, and Chaitra Badve^1,3,5

¹Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States, ²Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States, ³School of Medicine, Case Western Reserve University, Cleveland, OH, United States, ⁴Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, United States, ⁵Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH, United States, ⁶Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States, ⁷Neuro-Oncology Program & Brain Tumor Institute, Cleveland, OH, United States, ⁸Department of Radiology, Universith Hospitals Cleveland Medical Center, Cleveland, OH, United States

Synopsis

Keywords: Tumors (Post-Treatment), MR Fingerprinting, Glioblastoma; Local Recurrance; of Intratumoral Heterogeneity

Motivation: Post-treatment glioblastoma lesions often present with both local tumor recurrence and radiation necrosis. Segmenting within-lesion heterogeneity is clinically challenging. Cerebral blood volume (CBV) maps can inform high-risk areas, but with limited specificity.

Goal(s): We aim to extend the use of MR Fingerprinting (MRF) from whole-lesion classification to better characterize within-lesion heterogeneity and local recurrence, with histopathological validation.

Approach: We propose 1) a retrospective cohort (n=97) that develops MRF-CBV TR signatures from CBV-defined high-risk regions, and 2)a prospective validation cohort (n=14) that correlates the developed metrics with multi-location histopathological samples within lesion, and compares performance of CBV-defined versus biopsy-defined MRF signatures.

Impact: The MRF/CBV-informed local tumor recurrance signatures can improve characterization of intratumoral heterogeneity beyond CBV in recurrent glioblastomas. This pipeline will lead to more precise tumor sampling and better treatment response evaluation.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.